Table 2. Treatment Pathway and Outcomes.
| Characteristic | Treatment groupa | Between-group comparisonsb | P value | |
|---|---|---|---|---|
| Stratified care (n = 583) | Stepped care (n = 368) | |||
| Treatment pathway | ||||
| LIT | 251/583 (43.1) | 261/368 (70.9) | χ2 = 70.51 | <.001 |
| HITc | 332/583 (56.9) | 107/368 (29.1) | ||
| Treatment sessions, mean (SD) | 7.10 (5.31) | 5.84 (4.15) | Mann-Whitney U test, 121106.00 (SE, 4098.98) | <.001 |
| Treatment dropout | 166/542 (30.6) | 107/348 (30.7) | χ2 = 0.001 | .97 |
| Adherence to the stratified care model | 523/583 (89.7) | 233/368 (63.3) | χ2 = 96.41 | <.001 |
| κ Statistic | 0.81 | 0.22 | NA | NA |
| Treatment outcomes | ||||
| PHQ-9 depression RCSI | ||||
| Full sample | 264/505 (52.3) | 134/297 (45.1) | 1.40 (1.04-1.87) | .03 |
| Complex cases subsample | 63/160 (39.4) | 22/65 (33.8) | 1.28 (0.70-2.35) | .42 |
| Standard cases subsample | 201/345 (58.3) | 112/232 (48.3) | 1.50 (1.07-2.09) | .02 |
| GAD-7 anxiety RCSI | ||||
| Full sample | 266/538 (49.4) | 151/327 (46.2) | 1.19 (0.90-1.57) | .22 |
| Complex cases subsample | 52/160 (32.5) | 21/65 (32.3) | 1.02 (0.55-1.89) | .96 |
| Standard cases subsample | 214/378 (56.6) | 130/262 (49.6) | 1.35 (0.98-1.85) | .07 |
| IAPT reliable recovery, full sampled | 276/573 (48.2) | 152/348 (43.7) | 1.33 (1.01-1.75) | .04 |
Abbreviations: GAD-7, Generalized Anxiety Disorder questionnaire; HIT, high-intensity treatments; IAPT, Improving Access to Psychological Therapies; LIT, low-intensity treatments; PHQ-9, 9-item Patient Health Questionnaire; RCSI, reliable and clinically significant improvement.
Unless otherwise indicated, data are expressed as number/total number (%) of patients.
Unless otherwise indicated, data are expressed as odds ratio (95% CI).
Of these, 46 (13.9%) had prior LIT in the stratified care group and 28 (7.6%) had prior LIT in the stepped care group.
Requires patients with case-level PHQ-9 and/or GAD-7 symptoms to have (1) attained statistically reliable improvement on case-level measures, (2) to have subclinical symptoms on both measures after treatment, and (3) to not have statistically reliable deterioration on any of these measures after treatment.